⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
KURA News
Kura Oncology, Inc.
Form 8-K
sec.gov
KURA
Kura Oncology Reports Durable Clinical Activity of Darlifarnib Plus Cabozantinib in Cabozantinib-Naïve Clear Cell Renal Cell Carcinoma Patients at KCRS 2026
globenewswire.com
KURA
Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026
globenewswire.com
KURA
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
KURA
Kura Oncology And Kyowa Kirin Report Encouraging Long-Term Results for Ziftomenib / 7+3 Combination In Newly Diagnosed AML
globenewswire.com
KURA
Montara Therapeutics Appoints Andrew Miller to Board of Directors, Names Chief Medical Officer, and Promotes Chief Technology Officer
globenewswire.com
KURA
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
globenewswire.com
KURA
Form 8-K
sec.gov
KURA
Kura Oncology Highlights Darlifarnib’s Potential as a Foundational Combination Platform for KRAS-Mutant Cancers and Outlines Development Strategy
globenewswire.com
KURA
Kura Oncology and Kyowa Kirin Announce Publication in Blood of Ziftomenib plus Venetoclax / Azacitidine Combination in Patients with R/R NPM1-m AML
globenewswire.com
KURA